Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 08, 2016 9:50 PM ET


Company Overview of Apellis Pharmaceuticals, Inc.

Company Overview

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

6400 Westwind Way

Suite A

Crestwood, KY 40014

United States

Founded in 2009

11 Employees





Key Executives for Apellis Pharmaceuticals, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 43
Co-Founder and Chief Operating Officer
Age: 45
Co-Founder and Vice-President of Clinical Development
Age: 41
Co-Founder, Director, Chairman of Audit Committee and Member of Compensation Committee
Age: 43
Interim Chief Financial Officer
Age: 58
Compensation as of Fiscal Year 2015.

Apellis Pharmaceuticals, Inc. Key Developments

Apellis Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board

Apellis Pharmaceuticals, Inc. announced the formation of a Scientific Advisory Board. Carl Atkinson, PhD. Assistant Professor Microbiology & Immunology, Medical University of South Carolina, USA. Robert A. Brodsky, MD. Director, Division of Hematology, Professor of Medicine and Oncology, Johns Hopkins Hospital, USA. Gabriel J. Coscas, MD. Professor and Chairman of Ophthalmology, University of Paris XII, France. Peter Hillmen, MD, PhD. Professor of Experimental Hematology, Leeds Institute of Cancer & Pathology, UK. Claudia Kemper, PhD. Faculty, King's College, UK. Susan M. Lea, PhD. Chair and Professor of Microbiology, Co-Director, Oxford Martin Programme on Vaccines, Sir William Dunn School of Pathology, UK. Toby Maher, MD, PhD. Clinician Scientist, Pulmonologist and Honorary Senior Lecturer, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, UK. Philip J. Rosenfeld, MD, PhD. Professor of Ophthalmology, Bascom Palmer Eye Institute, USA. Johanna M. Seddon, MD, ScM. Professor of Ophthalmology, Tufts University School of Medicine, Boston, USA. Dave Singh, MD. Professor of Clinical Pharmacology and Respiratory Medicine, Medicines Evaluation Unit, UK. Jason S. Slakter, MD.Vitreous Retina Macular Consultants of New York and Clinical Professor of Ophthalmology, New York University School of Medicine, USA. Janet S. Sunness, MD. Medical Director of Richard E. Hoover Low Vision Rehabilitation Services, Greater Baltimore Medical Center, USA. Marsha Wills-Karp, PhD. Professor, Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, USA. Mike Yeadon, PhD. President and CEO, Ziarco, UK.

Apellis Pharmaceuticals, Inc. Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program

Apellis Pharmaceuticals, Inc. announced that it has begun the Phase I clinical trial of its drug compound APL-2 in patients suffering from age-related macular degeneration (AMD). The trial, labeled ASAP II, will focus on establishing safety of intravitreal injections of APL-2 and will be conducted in patients afflicted with wet AMD at multiple sites in the United States and Australia. The company plans to follow ASAP II with a larger Phase II trial in patients with geographic atrophy (the advanced stage of dry AMD) in the late spring of 2015.

Similar Private Companies By Industry

Company Name Region
Meso Scale Technologies, LLC United States
Velicept Therapeutics, Inc. United States
BioDisplay Technologies, Inc. United States
Pono Corp. United States
Aridis Pharmaceuticals Inc. United States

Recent Private Companies Transactions

Private Placement
December 24, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Apellis Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at